CCM
KIN

Coldstream Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Coldstream Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,885
Closed -$72K – 270
2016
Q1 		$72K Buy
+20,885
New +$73.8K 0.01% 254

Other funds holding KIN

AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Coldstream Capital Management's KIN Position: Q2 2016 in Review

Coldstream Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2016, closing a stake of 20,885 shares — an estimated $72K sold.

Coldstream Capital Management first reported a position in KIN in Q1 2016 and held it in 1 quarter. The position peaked at $72K in Q1 2016. 44 funds tracked by Wall St. Rank hold KIN as of Q2 2016.

  • Coldstream Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2016 after selling out during the quarter.
  • Coldstream Capital Management sold 20,885 Kindred Biosciences, Inc. shares in Q2 2016, an estimated $72K.
  • Coldstream Capital Management first reported a position in Kindred Biosciences, Inc. in Q1 2016 and held it in 1 quarter.
  • Coldstream Capital Management's Kindred Biosciences, Inc. position peaked at $72K in Q1 2016.
  • 44 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2016.

Based on Coldstream Capital Management's 13F filing for Q2 2016, filed 9 Aug 2016.